Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
In recent trading, Lightwave Logic Inc (LWLG) stock price has shown some volatility, fluctuating 8.55% over the last five trades and 11.88% over the past 30 trades. This represents a notable shift ...
Imagine a future where indoor wireless communication systems handle skyrocketing data demands and do so with unmatched ...
Zacks.com on MSN4d
SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease StudyShares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from ...
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...
科罗拉多州英格尔伍德 - 专门从事杂项塑料产品的Lightwave Logic, Inc. (NASDAQ:LWLG)公司报告称,其独立注册会计师事务所发生了变更。周一,Morison Cogen LLP辞去了其职务,公司审计委员会已任命Stephano Slack LLC为新的认证会计师。 Morison的辞职于2024年9月30日生效,这并非由于对2023年和2022财年财务报表的任何不利意见 ...
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues ...
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
智通财经APP获悉，Sage Therapeutics ...
Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback